Editorial
The emerging role of Interleukin-21 as an antineoplastic immunomodulatory treatment option
Abstract
As immunotherapy gathers momentum in the field of cancer therapeutics, a recently discovered chemokine, IL-21, has drawn attention as a promising immunomodulatory cytokine with antineoplastic effects. The aforementioned capacities of IL-21 have been investigated in phase I, II clinical trials where it has been utilized either as monotherapy or in combination with other agents. Extensive investigation and conduct of larger prospective trials are necessary for further evaluation of this promising immunotherapy modality.
